{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:43:04Z","timestamp":1758044584836,"version":"3.44.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br Dent J"],"published-print":{"date-parts":[[2025,9,12]]},"DOI":"10.1038\/s41415-025-8881-2","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T15:08:26Z","timestamp":1757689706000},"page":"316-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dental assessment pro forma for adult patients at risk of medication-related osteonecrosis of the jaw"],"prefix":"10.1038","volume":"239","author":[{"given":"Gemma","family":"Allen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Harford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"8881_CR4717","unstructured":"Scottish Dental Clinical Effectiveness Programme. Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw: Dental Clinical Guidance. 2017. Available at https:\/\/www.sdcep.org.uk\/media\/xtlp2uqx\/sdcep-mronj-guidance-extant-2024.pdf (accessed 1 March 2025)."},{"key":"8881_CR4720","doi-asserted-by":"crossref","unstructured":"Ruggiero S L, Dodson T B, Fantasia J et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw \u2212 2014 update. J Oral Maxillofac Surg 2014; 72: 1938-1956.","DOI":"10.1016\/j.joms.2014.04.031"},{"key":"8881_CR4723","unstructured":"Scottish Dental Clinical Effectiveness Programme. Drugs with MHRA safety update for MRONJ at 21 March 2024. 2024. Available at https:\/\/www.sdcep.org.uk\/media\/03pilvqg\/sdcep-mhra-mronj-drugs-list-2024.pdf (accessed 1 March 2025)."},{"key":"8881_CR4726","unstructured":"Scottish Dental Clinical Effectiveness Programme. Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw: Surveillance Review Report. 2024. Available at https:\/\/www.sdcep.org.uk\/media\/a3unkohl\/sdcep-mronj-surveillance-review-report_march-2024.pdf (accessed 1 March 2025)."},{"key":"8881_CR4729","unstructured":"Scottish Dental Clinical Effectiveness Programme. Oral Health Assessment and Review: Dental Clinical Guidance. 2012. Available at https:\/\/www.sdcep.org.uk\/media\/sy2ldxp2\/sdcep-ohar-version-1-0.pdf (accessed 1 March 2025)."},{"key":"8881_CR4732","unstructured":"National Institute of Health and Care Excellence. Dental checks: intervals between oral health reviews. 2004. Available at https:\/\/www.nice.org.uk\/Guidance\/CG19 (accessed 1 March 2025)."},{"key":"8881_CR4735","doi-asserted-by":"crossref","unstructured":"Khan S A, Kanis J A, Vasikaran S et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997; 12: 1700-1707.","DOI":"10.1359\/jbmr.1997.12.10.1700"},{"key":"8881_CR4738","unstructured":"Electronic Medicines Compendium. Prolia 60 mg solution in a pre-filled syringe. 2016. Available at https:\/\/www.medicines.org.uk\/emc\/product\/568\/rmms (accessed 1 March 2025)."},{"key":"8881_CR4741","doi-asserted-by":"crossref","unstructured":"Bone H G, Bolognese M A, Yuen C K et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011; 96: 972-980.","DOI":"10.1210\/jc.2010-1502"},{"key":"8881_CR4743","unstructured":"UK Government. Bevacizumab and sunitinib: risk of osteonecrosis of the jaw. 2014. Available at https:\/\/www.gov.uk\/drug-safety-update\/bevacizumab-and-sunitinib-risk-of-osteonecrosis-of-the-jaw (accessed 1 March 2025)."},{"key":"8881_CR4746","unstructured":"UK Government. Aflibercept (Zaltrap): minimising the risk of osteonecrosis of the jaw. 2016. Available at https:\/\/www.gov.uk\/drug-safety-update\/aflibercept-zaltrap-minimising-the-risk-of-osteonecrosis-of-the-jaw (accessed 1 March 2025)."},{"key":"8881_CR4749","doi-asserted-by":"crossref","unstructured":"Ruggiero S L, Dodson T B, Aghaloo T, Carlson E R, Ward B B, Kademani D. American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws \u2212 2022 update. J Oral Maxillofac Surg 2022; 80: 920-943.","DOI":"10.1016\/j.joms.2022.02.008"},{"key":"8881_CR4751","doi-asserted-by":"crossref","unstructured":"Yao S, Ding X, Rong G, Zhou J, Zhang B. Association between malignant diseases and medication-related osteonecrosis of the jaw (MRONJ): a systematic review and meta analysis. J Craniofac Surg 2023; 34: 669-673.","DOI":"10.1097\/SCS.0000000000009033"},{"key":"8881_CR4754","doi-asserted-by":"crossref","unstructured":"McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: a systematic review. Oral Dis 2018; 24: 527-536.","DOI":"10.1111\/odi.12708"},{"key":"8881_CR4756","doi-asserted-by":"crossref","unstructured":"Srivastava A, Nogueras Gonzalez G M, Geng Y et al. Medication-related osteonecrosis of the jaw in patients treated concurrently with antiresorptive and antiangiogenic agents: systematic review and meta-analysis. J Immunother Precis Oncol 2021; 4: 196-207.","DOI":"10.36401\/JIPO-21-14"},{"key":"8881_CR4758","doi-asserted-by":"crossref","unstructured":"Lo J C, O'Ryan F S, Gordon N P et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010; 68: 243-253.","DOI":"10.1016\/j.joms.2009.03.050"},{"key":"8881_CR4760","doi-asserted-by":"crossref","unstructured":"Nisi M, La Ferla F, Karapetsa D et al. Risk factors influencing BRONJ staging in patients receiving intravenous bisphosphonates: a multivariate analysis. Int J Oral Maxillofac Surg 2015; 44: 586-591.","DOI":"10.1016\/j.ijom.2015.01.014"},{"key":"8881_CR4763","doi-asserted-by":"crossref","unstructured":"Otto S, Troltzsch M, Jambrovic V et al. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg 2015; 43: 847-854.","DOI":"10.1016\/j.jcms.2015.03.039"},{"key":"8881_CR4765","doi-asserted-by":"crossref","unstructured":"Tsao C, Darby I, Ebeling P R et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg 2013; 71: 1360-1366.","DOI":"10.1016\/j.joms.2013.02.016"},{"key":"8881_CR4767","doi-asserted-by":"crossref","unstructured":"Thumbigere-Math V, Michalowicz B S, Hodges J S et al. Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw. J Periodontol 2014; 85: 226-233.","DOI":"10.1902\/jop.2013.130017"},{"key":"8881_CR4771","doi-asserted-by":"crossref","unstructured":"Schipmann S, Metzler P, R\u00f6ssle M et al. Osteopathology associated with bone resorption inhibitors \u2212 which role does Actinomyces play? A presentation of 51 cases with systematic review of the literature. J Oral Pathol Med 2013; 42: 587-593.","DOI":"10.1111\/jop.12038"},{"key":"8881_CR4773","unstructured":"Scottish Intercollegiate Guidelines Network. Management of osteoporosis and the prevention of fragility fractures. 2021. Available at https:\/\/www.sign.ac.uk\/our-guidelines\/management-of-osteoporosis-and-the-prevention-of-fragility-fractures\/ (accessed 1 March 2025)."},{"key":"8881_CR4776","doi-asserted-by":"crossref","unstructured":"Yarom N, Shapiro C L, Peterson D E et al. Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline. J Clin Oncol 2019; 37: 2270-2290.","DOI":"10.1200\/JCO.19.01186"},{"key":"8881_CR4779","doi-asserted-by":"crossref","unstructured":"Kyrgidis A, Tzellos T-G, Toulis K, Arora A, Kouvelas D, Triaridis S. An evidence-based review of risk-reductive strategies for osteonecrosis of the jaws among cancer patients. Curr Clin Pharmacol 2013; 8: 124-134.","DOI":"10.2174\/1574884711308020005"},{"key":"8881_CR4782","doi-asserted-by":"crossref","unstructured":"Bramati A, Girelli S, Farina G et al. Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. J Bone Miner Metab 2015; 33: 119-124.","DOI":"10.1007\/s00774-014-0566-x"},{"key":"8881_CR4784","doi-asserted-by":"crossref","unstructured":"Ripamonti C I, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009; 20: 137-145.","DOI":"10.1093\/annonc\/mdn526"},{"key":"8881_CR4786","unstructured":"UK Government. Mental Capacity Act 2005. 2005. Available at https:\/\/www.legislation.gov.uk\/ukpga\/2005\/9\/contents (accessed 1 March 2025)."},{"key":"8881_CR4789","doi-asserted-by":"crossref","unstructured":"Ottesen C, Schiodt M, Gotfredsen K. Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): a systematic review. Heliyon 2020; DOI: 10.1016\/j.heliyon.2020.e03795.","DOI":"10.1016\/j.heliyon.2020.e03795"}],"container-title":["British Dental Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41415-025-8881-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41415-025-8881-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41415-025-8881-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T15:08:31Z","timestamp":1757689711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41415-025-8881-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9,12]]}},"alternative-id":["8881"],"URL":"https:\/\/doi.org\/10.1038\/s41415-025-8881-2","relation":{},"ISSN":["0007-0610","1476-5373"],"issn-type":[{"value":"0007-0610","type":"print"},{"value":"1476-5373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}}]}}